TNF and inflammatory bowel disease: Geographic differences in study population baseline characteristics [e.g., disease severity at vedolizumab initiation, disease duration, prior anti-TNFα use (and number of prior therapies)], national treatment guidelines, and IBD management patterns may also account for variations in remission rates across geographic locations in our study.